<!DOCTYPE html>
<html class="client-js"><head>
  <meta charset=UTF-8"UTF-8">
  <title>Erlotinib</title>
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <script>
    function importScript() { return 1 } // this is to avoid the error from site.js
  </script>
  <link rel="canonical" href="https://en.wikipedia.org/wiki/Erlotinib">
  <link href="../-/s/css_modules/ext.cite.ux-enhancements.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.ux-enhancements.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/ext.cite.styles.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.styles.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/fi000001.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/skins.minerva.base.reset|skins.minerva.content.styles|ext.cite.style|site.styles|mobile.app.pagestyles.android|mediawiki.page.gallery.styles|mediawiki.skinning.content.parsoid.css" rel="stylesheet" type="text/css" class="">
  <link href="../-/s/css_modules/style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/style.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/content.parsoid.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/content.parsoid.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/inserted_style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/inserted_style.css" rel="stylesheet" type="text/css" class="">
  <script src="../-/j/js_modules/script.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/script.js" class=""></script><script src="../-/j/js_modules/masonry.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/masonry.min.js" class=""></script><script src="../-/j/js_modules/article_list_home.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/article_list_home.js" class=""></script><script src="../-/j/js_modules/images_loaded.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/images_loaded.min.js" class=""></script><script src="../-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" class=""></script>
<link type="root" href=""></head>

<body class="mediawiki mw-hide-empty-elt ns-0 ns-subject stable skin-minerva action-view animations">
  <div id="mw-mf-viewport" class="feature-header-v2">
    <div id="mw-mf-page-center">
      <div id="content" class="mw-body">
        <a id="top"></a>
        <div id="bodyContent" class="content mw-parser-output">
          
          <div id="mw-content-text" style="direction: ltr;"><h1 class="section-heading" tabindex="0" aria-haspopup="true" data-section-id="0">
  <span class="mw-headline" id="title_0">Erlotinib</span>
</h1>
<div id="mf-section-0" class="mf-section-0" aria-pressed="true" aria-expanded="true">
  <p><b>Erlotinib</b>, sold under the brand name <b>Tarceva</b> among others, is a medication used to treat non-small cell lung cancer (NSCLC) and pancreatic cancer.<span class="mw-ref" id="cite_ref-AHFS2019_2-0"><a href="#cite_note-AHFS2019-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> Specifically it is used for NSCLC with mutations in the epidermal growth factor receptor (EGFR) — either an exon 19 deletion (del19) or exon 21 (L858R) substitution mutation — which has spread to other parts of the body.<span class="mw-ref" id="cite_ref-AHFS2019_2-1"><a href="#cite_note-AHFS2019-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> It is taken by mouth.<span class="mw-ref" id="cite_ref-AHFS2019_2-2"><a href="#cite_note-AHFS2019-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></p>


<p></p>
<table class="infobox" style="width:22em;border-spacing:2px;"><caption><span>Erlotinib</span></caption><tbody><tr><td colspan="2" style="text-align:center"><figure-inline><img src="../I/m/Erlotinib_Structural_Formulae.png" tppabs="https://ptable.com/wiki/compounds/I/m/Erlotinib_Structural_Formulae.png" data-file-width="3181" data-file-height="1277" data-file-type="bitmap" height="100" width="250"></figure-inline></td></tr><tr><td colspan="2" style="text-align:center"><figure-inline><img src="../I/m/Erlotinib-1m17-3D-balls.png" tppabs="https://ptable.com/wiki/compounds/I/m/Erlotinib-1m17-3D-balls.png" data-file-width="1100" data-file-height="806" data-file-type="bitmap" height="183" width="250"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Clinical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Trade names</th><td>Tarceva</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Other names</th><td>Erlotinib hydrochloride</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">AHFS/Drugs.com</th><td><span><a href="javascript:if(confirm('https://www.drugs.com/monograph/erlotinib.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/erlotinib.html'" tppabs="https://www.drugs.com/monograph/erlotinib.html" class="external text external">Monograph</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">MedlinePlus</th><td><span><a href="javascript:if(confirm('https://medlineplus.gov/druginfo/meds/a605008.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://medlineplus.gov/druginfo/meds/a605008.html'" tppabs="https://medlineplus.gov/druginfo/meds/a605008.html" class="external text external">a605008</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">License data</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">EU</abbr></small><span>&nbsp;</span>EMA:<span>&nbsp;</span><span><a href="javascript:if(confirm('http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Erlotinib  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Erlotinib'" tppabs="http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Erlotinib" class="external text external">by INN</a></span></li>
<li><small><abbr class="country-name">US</abbr></small><span>&nbsp;</span>DailyMed:<span>&nbsp;</span><span><a href="javascript:if(confirm('https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Erlotinib  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Erlotinib'" tppabs="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Erlotinib" class="external text external">Erlotinib</a></span></li>
<li><small><abbr class="country-name">US</abbr></small><span>&nbsp;</span><span>FDA:<span>&nbsp;</span><a href="javascript:if(confirm('https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Erlotinib&SearchType=BasicSearch  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Erlotinib&SearchType=BasicSearch'" tppabs="https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Erlotinib&SearchType=BasicSearch" class="external text external">Erlotinib</a></span></li></ul></div>
</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pregnancy<br>category</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>C<span> </span><span class="mw-ref" id="cite_ref-Drugs.com_pregnancy_1-0"><a href="#cite_note-Drugs.com_pregnancy-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>N (Not classified yet)<span> </span><span class="mw-ref" id="cite_ref-Drugs.com_pregnancy_1-1"><a href="#cite_note-Drugs.com_pregnancy-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></li></ul>

<ul></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Routes of<br>administration</th><td>By mouth tablets</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ATC code</th><td><div class="plainlist"><ul><li>L01XE03<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=L01XE03  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=L01XE03'" tppabs="https://www.whocc.no/atc_ddd_index/?code=L01XE03" class="external text external">WHO</a></span>)<span> </span></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Legal status</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Legal status</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">UK</abbr>:</small><span> </span>POM (Prescription only)<span> </span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>℞-only<span> </span></li></ul></div>
</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Pharmacokinetic data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Bioavailability</th><td>59%</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Protein binding</th><td>95%</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Metabolism</th><td>Liver (mainly CYP3A4,  less CYP1A2)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Elimination <span class="nowrap">half-life</span></th><td>36.2 hrs (median)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Excretion</th><td>&gt;98% as metabolites, of which &gt;90% via feces, 9% via urine</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Identifiers</th></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">IUPAC name</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; text-align:left; padding-left:1.5em; text-indent:-1.5em; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><span style="font-size: 11px;"><i>N</i>-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)<br>quinazolin-4-amine</span></li></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CAS Number</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.commonchemistry.org/ChemicalDetail.aspx?ref=183321-74-6  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.commonchemistry.org/ChemicalDetail.aspx?ref=183321-74-6'" tppabs="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=183321-74-6" class="external text external">183321-74-6</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">PubChem <span style="font-weight:normal"><abbr>CID</abbr></span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://pubchem.ncbi.nlm.nih.gov/compound/176870  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubchem.ncbi.nlm.nih.gov/compound/176870'" tppabs="https://pubchem.ncbi.nlm.nih.gov/compound/176870" class="external text external">176870</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">IUPHAR/BPS</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4920  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4920'" tppabs="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4920" class="external text external">4920</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">DrugBank</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.drugbank.ca/drugs/DB00530  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugbank.ca/drugs/DB00530'" tppabs="https://www.drugbank.ca/drugs/DB00530" class="external text external">DB00530</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChemSpider</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.chemspider.com/Chemical-Structure.154044.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.chemspider.com/Chemical-Structure.154044.html'" tppabs="http://www.chemspider.com/Chemical-Structure.154044.html" class="external text external">154044</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">UNII</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=J4T82NDH7E  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=J4T82NDH7E'" tppabs="https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=J4T82NDH7E" class="external text external">J4T82NDH7E</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">KEGG</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.kegg.jp/entry/D07907  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.kegg.jp/entry/D07907'" tppabs="https://www.kegg.jp/entry/D07907" class="external text external">D07907</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEBI</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:114785  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:114785'" tppabs="https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:114785" class="external text external">CHEBI:114785</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEMBL</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL553  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL553'" tppabs="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL553" class="external text external">ChEMBL553</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CompTox Dashboard <span style="font-weight:normal">(<abbr>EPA</abbr>)</span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://comptox.epa.gov/dashboard/DTXSID8046454  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://comptox.epa.gov/dashboard/DTXSID8046454'" tppabs="https://comptox.epa.gov/dashboard/DTXSID8046454" class="external text external">DTXSID8046454</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;"><span>ECHA InfoCard</span></th><td><a href="javascript:if(confirm('https://echa.europa.eu/substance-information/-/substanceinfo/100.216.020  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://echa.europa.eu/substance-information/-/substanceinfo/100.216.020'" tppabs="https://echa.europa.eu/substance-information/-/substanceinfo/100.216.020" class="external text external">100.216.020</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Formula</th><td><span>C</span><sub>22</sub><span>H</span><sub>23</sub><span>N</span><sub>3</sub><span>O</span><sub>4</sub></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Molar mass</th><td><span class="nowrap">393.443</span><span>&nbsp;</span>g·mol<sup>−1</sup></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">3D model (JSmol)</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://chemapps.stolaf.edu/jmol/jmol.php?model=COCCOc1cc2c%28cc1OCCOC%29ncnc2Nc3cccc%28c3%29C%23C  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://chemapps.stolaf.edu/jmol/jmol.php?model=COCCOc1cc2c%28cc1OCCOC%29ncnc2Nc3cccc%28c3%29C%23C'" tppabs="https://chemapps.stolaf.edu/jmol/jmol.php?model=COCCOc1cc2c%28cc1OCCOC%29ncnc2Nc3cccc%28c3%29C%23C" class="external text external">Interactive image</a></span></li></ul></div></td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">SMILES</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">COCCOc1cc2c(cc1OCCOC)ncnc2Nc3cccc(c3)C#C</div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">InChI</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></div></li><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">Key:AAKJLRGGTJKAMG-UHFFFAOYSA-N<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><style data-mw-deduplicate="TemplateStyles:r886047488">.mw-parser-output .nobold{font-weight:normal}</style><span class="nobold"><span>&nbsp;</span><span>&nbsp;</span><span class="reflink  nourlexpansion"><a href="javascript:if(confirm('https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=464189825&page2=Erlotinib  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=464189825&page2=Erlotinib'" tppabs="https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=464189825&page2=Erlotinib" class="external text external">(verify)</a></span></span></td></tr></tbody></table>

<p>Common side effects include rash, diarrhea, muscle pain, joint pain, and cough.<span class="mw-ref" id="cite_ref-AHFS2019_2-3"><a href="#cite_note-AHFS2019-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span><span class="mw-ref" id="cite_ref-Tarceva_label_3-0"><a href="#cite_note-Tarceva_label-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> Serious side effects may include lung problems, kidney problems, liver failure, gastrointestinal perforation, stroke, and corneal ulceration.<span class="mw-ref" id="cite_ref-AHFS2019_2-4"><a href="#cite_note-AHFS2019-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> Use in pregnancy may harm the baby.<span class="mw-ref" id="cite_ref-AHFS2019_2-5"><a href="#cite_note-AHFS2019-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> It is a receptor tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor (EGFR).<span class="mw-ref" id="cite_ref-AHFS2019_2-6"><a href="#cite_note-AHFS2019-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></p>


<p>Erlotinib was approved for medical use in the United States in 2004.<span class="mw-ref" id="cite_ref-4"><a href="#cite_note-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span><span class="mw-ref" id="cite_ref-AHFS2019_2-7"><a href="#cite_note-AHFS2019-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span><span class="mw-ref" id="cite_ref-Tarceva_label_3-1"><a href="#cite_note-Tarceva_label-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> It is on the World Health Organization's List of Essential Medicines, which lists the safest and most effective medicines needed in a health system.<span class="mw-ref" id="cite_ref-WHO21st_5-0"><a href="#cite_note-WHO21st-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span> In the United States, <span>as of 2019</span>, it costs about US$8,832 per month.<span class="mw-ref" id="cite_ref-Price2019_6-0"><a href="#cite_note-Price2019-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span> In the United Kingdom this amount costs the NHS about £1,631.53 per month.<span class="mw-ref" id="cite_ref-BNF76_7-0"><a href="#cite_note-BNF76-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span></p>


</div><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Medical_uses">Medical uses</h2></summary>
    

    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Lung_cancer">Lung cancer</h3></summary>
    
<p>Erlotinib in unresectable non-small cell lung cancer when added to chemotherapy improves overall survival by 19%, and improved progression-free survival (PFS) by 29%, when compared to chemotherapy alone.<span class="mw-ref" id="cite_ref-8"><a href="#cite_note-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span><span class="mw-ref" id="cite_ref-9"><a href="#cite_note-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span> The U.S. Food and Drug Administration (FDA) approved erlotinib for the treatment of locally advanced or metastatic non-small cell lung cancer that has failed at least one prior chemotherapy regimen.<span class="mw-ref" id="cite_ref-10"><a href="#cite_note-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span></p>

<p>In lung cancer, erlotinib has been shown to be effective in patients with or without EGFR mutations, but appears to be more effective in patients with EGFR mutations.<span class="mw-ref" id="cite_ref-11"><a href="#cite_note-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span><span class="mw-ref" id="cite_ref-Qi_12-0"><a href="#cite_note-Qi-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span> Overall survival, progression-free survival and one-year survival are similar to standard second-line therapy (docetaxel or pemetrexed). Overall response rate is about 50% better than standard second-line chemotherapy.<span class="mw-ref" id="cite_ref-Qi_12-1"><a href="#cite_note-Qi-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span> Patients who are non-smokers, and light former smokers, with adenocarcinoma or subtypes like BAC are more likely to have EGFR mutations, but mutations can occur in all types of patients. A test for the EGFR mutation has been developed by Genzyme.<span class="mw-ref" id="cite_ref-13"><a href="#cite_note-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Pancreatic_cancer">Pancreatic cancer</h3></summary>
    
<p>In November 2005, the FDA approved erlotinib in combination with <a href="Gemcitabine.htm" tppabs="https://ptable.com/wiki/compounds/A/Gemcitabine" title="Gemcitabine">gemcitabine</a> for treatment of locally advanced, unresectable, or metastatic pancreatic cancer.<span class="mw-ref" id="cite_ref-14"><a href="#cite_note-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Resistance_to_treatment">Resistance to treatment</h3></summary>
    
<div class="thumb tright"><div class="thumbinner" style="width:222px"><img src="../I/m/ErbB1_Erlotinib.jpg" tppabs="https://ptable.com/wiki/compounds/I/m/ErbB1_Erlotinib.jpg" data-file-width="500" data-file-height="500" data-file-type="bitmap" height="220" width="220"><div class="thumbcaption" style="text-align: left">Erlotinib bound to ErbB1 at 2.6A resolution; surface colour indicates hydrophobicity.</div></div></div>
<p>As with other ATP competitive small molecule tyrosine kinase inhibitors, such as <a href="Imatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Imatinib" title="Imatinib">imatinib</a> in CML, patients rapidly develop resistance. In the case of erlotinib this typically occurs 8–12 months from the start of treatment. Over 50% of resistance is caused by a mutation in the ATP binding pocket of the EGFR kinase domain involving substitution of a small polar threonine residue with a large nonpolar methionine residue (T790M).<span class="mw-ref" id="cite_ref-pmid17085664_15-0"><a href="#cite_note-pmid17085664-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span></p>

<p>Approximately 20% of drug resistance is caused by amplification of the hepatocyte growth factor receptor, which drives ERBB3 dependent activation of PI3K.<span class="mw-ref" id="cite_ref-pmid17463250_16-0"><a href="#cite_note-pmid17463250-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span><span class="mw-ref" id="cite_ref-pmid18093943_17-0"><a href="#cite_note-pmid18093943-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Side_effects">Side effects</h2></summary>
    


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Common">Common</h3></summary>
    
<ul><li>Rash occurs in the majority of patients.  This resembles acne and primarily involves the face and neck.  It is self-limited and resolves in the majority of cases, even with continued use.  Some clinical studies have indicated a correlation between the severity of the skin reactions and increased survival though this has not been quantitatively assessed.<span class="mw-ref" id="cite_ref-18"><a href="#cite_note-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span> The <i>Journal of Clinical Oncology</i> reported in 2004 that "cutaneous [skin] rash seems to be a surrogate marker of clinical benefit, but this finding should be confirmed in ongoing and future studies."<span class="mw-ref" id="cite_ref-19"><a href="#cite_note-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span> The newsletter <i>Lung Cancer Frontiers</i> reported in its October 2003 issue, "Patients with moderate to severe cutaneous reactions [rashes] have a far better survival, than those with only mild reactions and much better than those with no cutaneous manifestations of drug effects."<span class="mw-ref" id="cite_ref-20"><a href="#cite_note-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span></li>
<li>Diarrhea</li>
<li>Loss of appetite</li>
<li>Fatigue</li>
<li>Partial hair loss (by strands, not typically in clumps)</li></ul>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Rare">Rare</h3></summary>
    
<ul><li>interstitial pneumonitis, which is characterized by cough and increased dyspnea. This may be severe and must be considered among those patients whose breathing acutely worsens.</li>
<li>ingrown hairs, such as eyelashes</li>
<li>gastrointestinal tract toxicity
<ul><li>serious or fatal gastrointestinal tract perforations</li></ul></li>
<li>skin toxicity
<ul><li>bullous, blistering, and exfoliative skin conditions (some fatal)</li>
<li>Stevens–Johnson syndrome/toxic epidermal necrolysis <span class="mw-ref" id="cite_ref-21"><a href="#cite_note-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span></li></ul></li>
<li>ocular disorders
<ul><li>corneal lesions</li></ul></li>
<li>Pulmonary toxicity
<ul><li>interstitial pneumonitis</li>
<li>bronchiolitis obliterans with organizing pneumonia (BOOP)</li>
<li>pulmonary fibrosis</li>
<li>fatal asymmetric interstitial lung disease<span class="mw-ref" id="cite_ref-22"><a href="#cite_note-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span></li></ul></li></ul>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Interactions">Interactions</h2></summary>
    
<p>Erlotinib is not a substrate for either of hepatic OATPs (OATP1B1 or OATP1B3).<span class="mw-ref" id="cite_ref-pmid24643910_23-0"><a href="#cite_note-pmid24643910-23" style="counter-reset: mw-Ref 23;"><span class="mw-reflink-text">[23]</span></a></span> Also, erlotinib is not an inhibitor of OATP-1B1 or OATP-1B3 transporter.<span class="mw-ref" id="cite_ref-Khurana_V_2014_24-0"><a href="#cite_note-Khurana_V_2014-24" style="counter-reset: mw-Ref 24;"><span class="mw-reflink-text">[24]</span></a></span></p>

<p>Erlotinib is mainly metabolized by the liver enzyme CYP3A4. Compounds which induce this enzyme (i.e. stimulate its production), such as St John's wort, can lower erlotinib concentrations, while inhibitors can increase concentrations.<span class="mw-ref" id="cite_ref-25"><a href="#cite_note-25" style="counter-reset: mw-Ref 25;"><span class="mw-reflink-text">[25]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Mechanism">Mechanism</h2></summary>
    
<p>Erlotinib is an epidermal growth factor receptor inhibitor (EGFR inhibitor). The drug follows Iressa (<a href="Gefitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Gefitinib" title="Gefitinib">gefitinib</a>), which was the first drug of this type.  Erlotinib specifically targets the epidermal growth factor receptor (EGFR) tyrosine kinase, which is highly expressed and occasionally mutated in various forms of cancer.  It binds in a reversible fashion to the <a href="Adenosine_triphosphate.htm" tppabs="https://ptable.com/wiki/compounds/A/Adenosine_triphosphate" title="Adenosine triphosphate">adenosine triphosphate</a> (ATP) binding site of the receptor.<span class="mw-ref" id="cite_ref-26"><a href="#cite_note-26" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></span>  For the signal to be transmitted, two EGFR molecules need to come together to form a homodimer.  These then use the molecule of ATP to trans-phosphorylate each other on tyrosine residues, which generates phosphotyrosine residues, recruiting the phosphotyrosine-binding proteins to EGFR to assemble protein complexes that transduce signal cascades to the nucleus or activate other cellular biochemical processes.   When erlotinib binds to EGFR, formation of phosphotyrosine residues in EGFR is not possible and the signal cascades are not initiated.</p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Society_and_culture">Society and culture</h2></summary>
    
<p>It is marketed in the United States by Genentech<span class="mw-ref" id="cite_ref-Tarceva_label_3-2"><a href="#cite_note-Tarceva_label-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> and OSI Pharmaceuticals<span class="mw-ref" id="cite_ref-27"><a href="#cite_note-27" style="counter-reset: mw-Ref 27;"><span class="mw-reflink-text">[27]</span></a></span> and elsewhere by Roche.<span class="mw-ref" id="cite_ref-28"><a href="#cite_note-28" style="counter-reset: mw-Ref 28;"><span class="mw-reflink-text">[28]</span></a></span></p>

<p>The drug's U.S. patent will expire in 2020.<span class="mw-ref" id="cite_ref-29"><a href="#cite_note-29" style="counter-reset: mw-Ref 29;"><span class="mw-reflink-text">[29]</span></a></span> In May 2012, the US District Court of Delaware passed an order in favor of OSI Pharmaceutical LLC against Mylan Pharmaceuticals upholding the validity of the patent for Erlotinib. In India, generic pharmaceutical firm Cipla is battling with Roche against the Indian patent for this drug.<span class="mw-ref" id="cite_ref-30"><a href="#cite_note-30" style="counter-reset: mw-Ref 30;"><span class="mw-reflink-text">[30]</span></a></span><span class="mw-ref" id="cite_ref-31"><a href="#cite_note-31" style="counter-reset: mw-Ref 31;"><span class="mw-reflink-text">[31]</span></a></span></p>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Price">Price</h3></summary>
    
<p>In the United States, <span>as of 2019</span>, it costs about US$8,832 per month.<span class="mw-ref" id="cite_ref-Price2019_6-1"><a href="#cite_note-Price2019-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span> In the United Kingdom this amount costs the NHS about £1,631.53 per month.<span class="mw-ref" id="cite_ref-BNF76_7-1"><a href="#cite_note-BNF76-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="References">References</h2></summary>
    
<div class="reflist " style=" list-style-type: decimal;">
<div class="mw-references-wrap mw-references-columns"><ol class="mw-references references"><li id="cite_note-Drugs.com_pregnancy-1"> <span id="mw-reference-text-cite_note-Drugs.com_pregnancy-1" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/pregnancy/erlotinib.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/pregnancy/erlotinib.html'" tppabs="https://www.drugs.com/pregnancy/erlotinib.html" class="external text external">"Erlotinib (Tarceva) Use During Pregnancy"</a>. <i>Drugs.com</i>. 1 November 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">23 December</span> 2019</span>.</cite></span></li><li id="cite_note-AHFS2019-2"> <span id="mw-reference-text-cite_note-AHFS2019-2" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/monograph/erlotinib.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/erlotinib.html'" tppabs="https://www.drugs.com/monograph/erlotinib.html" class="external text external">"Erlotinib Monograph for Professionals"</a>. <i>Drugs.com</i><span class="reference-accessdate">. Retrieved <span class="nowrap">12 November</span> 2019</span>.</cite></span></li><li id="cite_note-Tarceva_label-3"> <span id="mw-reference-text-cite_note-Tarceva_label-3" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=57bccb29-1c47-4c64-ab6a-77960a91cc20  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=57bccb29-1c47-4c64-ab6a-77960a91cc20'" tppabs="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=57bccb29-1c47-4c64-ab6a-77960a91cc20" class="external text external">"Tarceva- erlotinib hydrochloride tablet"</a>. <i>DailyMed</i>. 12 December 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">23 December</span> 2019</span>.</cite></span></li><li id="cite_note-4"> <span id="mw-reference-text-cite_note-4" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-743_Tarceva.cfm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-743_Tarceva.cfm'" tppabs="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-743_Tarceva.cfm" class="external text external">"Drug Approval Package: Tarceva (Erlotinib) NDA #021743"</a>. <i>U.S. Food and Drug Administration (FDA)</i>. 28 March 2005<span class="reference-accessdate">. Retrieved <span class="nowrap">23 December</span> 2019</span>.</cite></span></li><li id="cite_note-WHO21st-5"> <span id="mw-reference-text-cite_note-WHO21st-5" class="mw-reference-text"><cite id="CITEREFOrganization2019" class="citation journal cs1">Organization, World Health (2019). "World Health Organization model list of essential medicines: 21st list 2019". hdl:<a href="javascript:if(confirm('https://hdl.handle.net/10665%2F325771  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://hdl.handle.net/10665%2F325771'" tppabs="https://hdl.handle.net/10665%2F325771" class="external text external">10665/325771</a>.</cite><span> </span><span class="cs1-hidden-error error citation-comment">Cite journal requires <code class="cs1-code"><span>|</span>journal=</code> (help)</span></span></li><li id="cite_note-Price2019-6"> <span id="mw-reference-text-cite_note-Price2019-6" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/price-guide/tarceva  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/price-guide/tarceva'" tppabs="https://www.drugs.com/price-guide/tarceva" class="external text external">"Tarceva Prices, Coupons &amp; Patient Assistance Programs"</a>. <i>Drugs.com</i>.</cite></span></li><li id="cite_note-BNF76-7"> <span id="mw-reference-text-cite_note-BNF76-7" class="mw-reference-text"><cite class="citation book cs1"><i>British national formulary<span>&nbsp;</span>: BNF 76</i> (76 ed.). Pharmaceutical Press. 2018. p.<span>&nbsp;</span>950. ISBN<span>&nbsp;</span><bdi>9780857113382</bdi>.</cite></span></li><li id="cite_note-8"> <span id="mw-reference-text-cite_note-8" class="mw-reference-text"><a href="javascript:if(confirm('http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=32756  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=32756'" tppabs="http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=32756" class="external text external">2009 - SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC.</a></span></li><li id="cite_note-9"> <span id="mw-reference-text-cite_note-9" class="mw-reference-text"><a href="javascript:if(confirm('http://www.tarceva.com/docs/Indication_Announcement_Letter.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.tarceva.com/docs/Indication_Announcement_Letter.pdf'" tppabs="http://www.tarceva.com/docs/Indication_Announcement_Letter.pdf" class="external text external">April 2010 - Tarceva Indication Announcement Letter</a></span></li><li id="cite_note-10"> <span id="mw-reference-text-cite_note-10" class="mw-reference-text"><cite id="CITEREFCohenJohnsonChenSridhara2005" class="citation journal cs1">Cohen, Martin H.; Johnson, John R.; Chen, Yeh-Fong; Sridhara, Rajeshwari; Pazdur, Richard (August 2005). "FDA drug approval summary: erlotinib (Tarceva) tablets". <i>The Oncologist</i>. <b>10</b> (7): 461–466. doi:<a href="javascript:if(confirm('https://doi.org/10.1634%2Ftheoncologist.10-7-461  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1634%2Ftheoncologist.10-7-461'" tppabs="https://doi.org/10.1634%2Ftheoncologist.10-7-461" class="external text external">10.1634/theoncologist.10-7-461</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1083-7159  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1083-7159'" tppabs="https://www.worldcat.org/issn/1083-7159" class="external text external">1083-7159</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16079312  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16079312'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16079312" class="external text external">16079312</a>.</cite></span></li><li id="cite_note-11"> <span id="mw-reference-text-cite_note-11" class="mw-reference-text"><cite id="CITEREFKobayashiHagiwara2013" class="citation journal cs1">Kobayashi K, Hagiwara K (2013). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3591525  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3591525'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3591525" class="external text external">"Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC)"</a>. <i>Targeted Oncology</i>. <b>8</b> (1): 27–33. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fs11523-013-0258-9  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fs11523-013-0258-9'" tppabs="https://doi.org/10.1007%2Fs11523-013-0258-9" class="external text external">10.1007/s11523-013-0258-9</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3591525  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3591525'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3591525" class="external text external">3591525</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23361373  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23361373'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23361373" class="external text external">23361373</a>.</cite></span></li><li id="cite_note-Qi-12"> <span id="mw-reference-text-cite_note-Qi-12" class="mw-reference-text"><cite id="CITEREFQiShenLinSun2012" class="citation journal cs1">Qi WX, Shen Z, Lin F,  et al. (2012). <a href="javascript:if(confirm('https://doi.org/10.7314/APJCP.2012.13.10.5177  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.7314/APJCP.2012.13.10.5177'" tppabs="https://doi.org/10.7314/APJCP.2012.13.10.5177" class="external text external">"Comparison of the efficacy and safety of EFGR tyrosine kinase inhibitor monotherapy with standard second-line chemotherapy in previously treated advanced non-small-cell lung cancer: A systematic review and meta-analysis"</a>. <i>Asian Pacific Journal of Cancer Prevention</i>. <b>13</b> (10): 5177–5182. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.7314%2FAPJCP.2012.13.10.5177  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.7314%2FAPJCP.2012.13.10.5177'" tppabs="https://doi.org/10.7314%2FAPJCP.2012.13.10.5177" class="external text external">10.7314/APJCP.2012.13.10.5177</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23244131  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23244131'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23244131" class="external text external">23244131</a>.</cite></span></li><li id="cite_note-13"> <span id="mw-reference-text-cite_note-13" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.roche.com/investors/updates/inv-update-2010-11-23.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.roche.com/investors/updates/inv-update-2010-11-23.htm'" tppabs="https://www.roche.com/investors/updates/inv-update-2010-11-23.htm" class="external text external">"Roche obtains license for EGFR lung cancer assays and will develop Tarceva companion diagnostic test"</a>. <i>www.roche.com</i><span class="reference-accessdate">. Retrieved <span class="nowrap">10 January</span> 2020</span>.</cite></span></li><li id="cite_note-14"> <span id="mw-reference-text-cite_note-14" class="mw-reference-text"><cite id="CITEREFTakimotoCalvo2009" class="citation cs2">Takimoto CH, Calvo E (15 April 2009), <a href="javascript:if(confirm('http://www.cancernetwork.com/cancer-management-11/chapter03/article/10165/1402628  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.cancernetwork.com/cancer-management-11/chapter03/article/10165/1402628'" tppabs="http://www.cancernetwork.com/cancer-management-11/chapter03/article/10165/1402628" class="external text external"><i>Principles of Oncologic Pharmacotherapy</i></a></cite></span></li><li id="cite_note-pmid17085664-15"> <span id="mw-reference-text-cite_note-pmid17085664-15" class="mw-reference-text"><cite id="CITEREFBalakGongRielySomwar2006" class="citation journal cs1">Balak MN, Gong Y, Riely GJ,  et al. (2006). <a href="javascript:if(confirm('https://doi.org/10.1158/1078-0432.CCR-06-1570  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1158/1078-0432.CCR-06-1570'" tppabs="https://doi.org/10.1158/1078-0432.CCR-06-1570" class="external text external">"Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors"</a>. <i>Clin Cancer Res</i>. <b>12</b> (1): 6494–501. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1158%2F1078-0432.CCR-06-1570  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1158%2F1078-0432.CCR-06-1570'" tppabs="https://doi.org/10.1158%2F1078-0432.CCR-06-1570" class="external text external">10.1158/1078-0432.CCR-06-1570</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17085664  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17085664'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17085664" class="external text external">17085664</a>.</cite></span></li><li id="cite_note-pmid17463250-16"> <span id="mw-reference-text-cite_note-pmid17463250-16" class="mw-reference-text"><cite id="CITEREFEngelmanZejnullahuMitsudomiSong2007" class="citation journal cs1">Engelman JA, Zejnullahu K, Mitsudomi T,  et al. (2007). "MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling". <i>Science</i>. <b>316</b> (5827): 1039–43. Bibcode:<a href="javascript:if(confirm('https://ui.adsabs.harvard.edu/abs/2007Sci...316.1039E  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://ui.adsabs.harvard.edu/abs/2007Sci...316.1039E'" tppabs="https://ui.adsabs.harvard.edu/abs/2007Sci...316.1039E" class="external text external">2007Sci...316.1039E</a>. doi:<a href="javascript:if(confirm('https://doi.org/10.1126%2Fscience.1141478  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1126%2Fscience.1141478'" tppabs="https://doi.org/10.1126%2Fscience.1141478" class="external text external">10.1126/science.1141478</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17463250  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17463250'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17463250" class="external text external">17463250</a>.</cite></span></li><li id="cite_note-pmid18093943-17"> <span id="mw-reference-text-cite_note-pmid18093943-17" class="mw-reference-text"><cite id="CITEREFEBeanBrennanShihRiely2007" class="citation journal cs1">EBean J, Brennan C, Shih JY,  et al. (2007). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409244  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409244'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409244" class="external text external">"MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib"</a>. <i>PNAS</i>. <b>104</b> (52): 20932–7. Bibcode:<a href="javascript:if(confirm('https://ui.adsabs.harvard.edu/abs/2007PNAS..10420932B  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://ui.adsabs.harvard.edu/abs/2007PNAS..10420932B'" tppabs="https://ui.adsabs.harvard.edu/abs/2007PNAS..10420932B" class="external text external">2007PNAS..10420932B</a>. doi:<a href="javascript:if(confirm('https://doi.org/10.1073%2Fpnas.0710370104  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1073%2Fpnas.0710370104'" tppabs="https://doi.org/10.1073%2Fpnas.0710370104" class="external text external">10.1073/pnas.0710370104</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409244  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409244'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409244" class="external text external">2409244</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18093943  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18093943'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18093943" class="external text external">18093943</a>.</cite></span></li><li id="cite_note-18"> <span id="mw-reference-text-cite_note-18" class="mw-reference-text"><cite id="CITEREFDudekKmakKoopmeinersKeshtgarpour2006" class="citation journal cs1">Dudek AZ, Kmak KL, Koopmeiners J,  et al. (2006). "Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer". <i>Lung Cancer</i>. <b>51</b> (1): 89–96. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.lungcan.2005.09.002  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.lungcan.2005.09.002'" tppabs="https://doi.org/10.1016%2Fj.lungcan.2005.09.002" class="external text external">10.1016/j.lungcan.2005.09.002</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16290256  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16290256'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16290256" class="external text external">16290256</a>.</cite></span></li><li id="cite_note-19"> <span id="mw-reference-text-cite_note-19" class="mw-reference-text"><cite id="CITEREFPérez-SolerChachouaHammondRowinsky2004" class="citation journal cs1">Pérez-Soler R, Chachoua A, Hammond LA,  et al. (15 August 2004). "Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer". <i>Journal of Clinical Oncology</i>. <b>22</b> (16): 3238–3247. doi:<a href="javascript:if(confirm('https://doi.org/10.1200%2FJCO.2004.11.057  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1200%2FJCO.2004.11.057'" tppabs="https://doi.org/10.1200%2FJCO.2004.11.057" class="external text external">10.1200/JCO.2004.11.057</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0732-183X  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0732-183X'" tppabs="https://www.worldcat.org/issn/0732-183X" class="external text external">0732-183X</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15310767  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15310767'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15310767" class="external text external">15310767</a>.</cite></span></li><li id="cite_note-20"> <span id="mw-reference-text-cite_note-20" class="mw-reference-text"><cite id="CITEREFThomas_L._Petty,_M.D.2003" class="citation journal cs1">Thomas L. Petty, M.D. (2003). "Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer". <i>Journal of Clinical Oncology</i>. <b>1</b> (17): 3–4.</cite></span></li><li id="cite_note-21"> <span id="mw-reference-text-cite_note-21" class="mw-reference-text"><cite id="CITEREFLiKameneckaCameron2010" class="citation journal cs1">Li X, Kamenecka TM, Cameron MD (2010). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202369  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202369'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202369" class="external text external">"Cytochrome P450-mediated bioactivation of the epidermal growth factor receptor inhibitor erlotinib to a reactive electrophile"</a>. <i>Drug Metabolism and Disposition: The Biological Fate of Chemicals</i>. <b>38</b> (7): 1238–45. doi:<a href="javascript:if(confirm('https://doi.org/10.1124%2Fdmd.109.030361  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1124%2Fdmd.109.030361'" tppabs="https://doi.org/10.1124%2Fdmd.109.030361" class="external text external">10.1124/dmd.109.030361</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0090-9556  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0090-9556'" tppabs="https://www.worldcat.org/issn/0090-9556" class="external text external">0090-9556</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202369  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202369'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202369" class="external text external">3202369</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/20382753  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/20382753'" tppabs="https://pubmed.ncbi.nlm.nih.gov/20382753" class="external text external">20382753</a>.</cite></span></li><li id="cite_note-22"> <span id="mw-reference-text-cite_note-22" class="mw-reference-text"><cite id="CITEREFRenLiLiZhao2012" class="citation journal cs1">Ren S, Li Y, Li W,  et al. (2012). "Fatal asymmetric interstitial lung disease after erlotinib for lung cancer". <i>Respiration</i>. <b>84</b> (5): 431–5. doi:<a href="javascript:if(confirm('https://doi.org/10.1159%2F000339508  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1159%2F000339508'" tppabs="https://doi.org/10.1159%2F000339508" class="external text external">10.1159/000339508</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22889962  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22889962'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22889962" class="external text external">22889962</a>.</cite></span></li><li id="cite_note-pmid24643910-23"> <span id="mw-reference-text-cite_note-pmid24643910-23" class="mw-reference-text"><cite id="CITEREFKhuranaMinochaPalMitra2014" class="citation journal cs1">Khurana V, Minocha M, Pal D,  et al. (March 2014). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407685  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407685'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407685" class="external text external">"Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors"</a>. <i>Drug Metabol Drug Interact</i>. <b>29</b> (3): 179–90. doi:<a href="javascript:if(confirm('https://doi.org/10.1515%2Fdmdi-2013-0062  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1515%2Fdmdi-2013-0062'" tppabs="https://doi.org/10.1515%2Fdmdi-2013-0062" class="external text external">10.1515/dmdi-2013-0062</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407685  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407685'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407685" class="external text external">4407685</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24643910  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24643910'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24643910" class="external text external">24643910</a>.</cite></span></li><li id="cite_note-Khurana_V_2014-24"> <span id="mw-reference-text-cite_note-Khurana_V_2014-24" class="mw-reference-text"><cite class="citation journal cs1">Khurana V, Minocha M, Pal D,  et al. (May 2014). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407688  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407688'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407688" class="external text external">"Inhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitors"</a>. <i>Drug Metabol Drug Interact</i>. <b>29</b> (4): 249–59. doi:<a href="javascript:if(confirm('https://doi.org/10.1515%2Fdmdi-2014-0014  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1515%2Fdmdi-2014-0014'" tppabs="https://doi.org/10.1515%2Fdmdi-2014-0014" class="external text external">10.1515/dmdi-2014-0014</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407688  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407688'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407688" class="external text external">4407688</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24807167  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24807167'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24807167" class="external text external">24807167</a>.</cite></span></li><li id="cite_note-25"> <span id="mw-reference-text-cite_note-25" class="mw-reference-text"><cite id="CITEREFHaberfeld,_H2010" class="citation book cs1">Haberfeld, H, ed. (2010). <i>Austria-Codex</i> (in German) (2010/2011 ed.). Vienna: Österreichischer Apothekerverlag.</cite></span></li><li id="cite_note-26"> <span id="mw-reference-text-cite_note-26" class="mw-reference-text"><cite id="CITEREFRaymondFaivreArmand2000" class="citation journal cs1">Raymond E, Faivre S, Armand JP (2000). "Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy". <i>Drugs</i>. 60 Suppl 1: 15–23, discussion 41–2. doi:<a href="javascript:if(confirm('https://doi.org/10.2165%2F00003495-200060001-00002  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2165%2F00003495-200060001-00002'" tppabs="https://doi.org/10.2165%2F00003495-200060001-00002" class="external text external">10.2165/00003495-200060001-00002</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/11129168  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/11129168'" tppabs="https://pubmed.ncbi.nlm.nih.gov/11129168" class="external text external">11129168</a>.</cite></span></li><li id="cite_note-27"> <span id="mw-reference-text-cite_note-27" class="mw-reference-text"><cite id="CITEREFAdis_International_Ltd2003" class="citation journal cs1">Adis International Ltd (2003). "Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415". <i>Drugs in R&amp;D</i>. <b>4</b> (4): 243–248. doi:<a href="javascript:if(confirm('https://doi.org/10.2165%2F00126839-200304040-00006  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2165%2F00126839-200304040-00006'" tppabs="https://doi.org/10.2165%2F00126839-200304040-00006" class="external text external">10.2165/00126839-200304040-00006</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1174-5886  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1174-5886'" tppabs="https://www.worldcat.org/issn/1174-5886" class="external text external">1174-5886</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12848590  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12848590'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12848590" class="external text external">12848590</a>.</cite></span></li><li id="cite_note-28"> <span id="mw-reference-text-cite_note-28" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.genomeweb.com/diagnostics/fda-approves-roche-test-cdx-tarceva-treating-certain-nsclc-patients  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.genomeweb.com/diagnostics/fda-approves-roche-test-cdx-tarceva-treating-certain-nsclc-patients'" tppabs="https://www.genomeweb.com/diagnostics/fda-approves-roche-test-cdx-tarceva-treating-certain-nsclc-patients" class="external text external">"FDA Approves Roche Test as CDx for Tarceva for Treating Certain NSCLC Patients"</a>. <i>GenomeWeb</i><span class="reference-accessdate">. Retrieved <span class="nowrap">10 January</span> 2020</span>.</cite></span></li><li id="cite_note-29"> <span id="mw-reference-text-cite_note-29" class="mw-reference-text"><a href="javascript:if(confirm('http://drugpatentwatch.com/p/ingredient/erlotinib  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://drugpatentwatch.com/p/ingredient/erlotinib'" tppabs="http://drugpatentwatch.com/p/ingredient/erlotinib" class="external free external">http://drugpatentwatch.com/p/ingredient/erlotinib</a>, "Details for Generic Name: erlotinib", DrugPatentWatch.com</span></li><li id="cite_note-30"> <span id="mw-reference-text-cite_note-30" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.gabionline.net/Generics/News/Roche-and-India-s-Glenmark-reach-truce-over-generic-Tarceva  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.gabionline.net/Generics/News/Roche-and-India-s-Glenmark-reach-truce-over-generic-Tarceva'" tppabs="http://www.gabionline.net/Generics/News/Roche-and-India-s-Glenmark-reach-truce-over-generic-Tarceva" class="external text external">"Roche and India's Glenmark reach truce over generic Tarceva"</a>. <i>GaBI Online</i>. 22 January 2016. <a href="javascript:if(confirm('https://web.archive.org/web/20191224075230/http://www.gabionline.net/Generics/News/Roche-and-India-s-Glenmark-reach-truce-over-generic-Tarceva  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20191224075230/http://www.gabionline.net/Generics/News/Roche-and-India-s-Glenmark-reach-truce-over-generic-Tarceva'" tppabs="https://web.archive.org/web/20191224075230/http://www.gabionline.net/Generics/News/Roche-and-India-s-Glenmark-reach-truce-over-generic-Tarceva" class="external text external">Archived</a> from the original on 24 December 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">23 December</span> 2019</span>.</cite></span></li><li id="cite_note-31"> <span id="mw-reference-text-cite_note-31" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://economictimes.indiatimes.com/cancer-drug-supreme-court-allows-cipla-to-withdraw-appeal-against-roche/articleshow/59176743.cms  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://economictimes.indiatimes.com/cancer-drug-supreme-court-allows-cipla-to-withdraw-appeal-against-roche/articleshow/59176743.cms'" tppabs="https://economictimes.indiatimes.com/cancer-drug-supreme-court-allows-cipla-to-withdraw-appeal-against-roche/articleshow/59176743.cms" class="external text external">"Cancer drug: Supreme Court allows Cipla to withdraw appeal against Roche"</a>. <i>The Economic Times</i>. 16 June 2017. <a href="javascript:if(confirm('https://web.archive.org/web/20191224075759/https://economictimes.indiatimes.com/cancer-drug-supreme-court-allows-cipla-to-withdraw-appeal-against-roche/articleshow/59176743.cms  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20191224075759/https://economictimes.indiatimes.com/cancer-drug-supreme-court-allows-cipla-to-withdraw-appeal-against-roche/articleshow/59176743.cms'" tppabs="https://web.archive.org/web/20191224075759/https://economictimes.indiatimes.com/cancer-drug-supreme-court-allows-cipla-to-withdraw-appeal-against-roche/articleshow/59176743.cms" class="external text external">Archived</a> from the original on 24 December 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">23 December</span> 2019</span>.</cite></span></li></ol></div></div>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="External_links">External links</h2></summary>
    
<ul><li><cite class="citation web cs1"><a href="javascript:if(confirm('https://druginfo.nlm.nih.gov/drugportal/name/erlotinib  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://druginfo.nlm.nih.gov/drugportal/name/erlotinib'" tppabs="https://druginfo.nlm.nih.gov/drugportal/name/erlotinib" class="external text external">"Erlotinib"</a>. <i>Drug Information Portal</i>. U.S. National Library of Medicine.</cite></li>
<li><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.cancer.gov/publications/dictionaries/cancer-drug/def/erlotinib-hydrochloride  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/erlotinib-hydrochloride'" tppabs="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/erlotinib-hydrochloride" class="external text external">"Erlotinib"</a>. <i>National Cancer Institute</i>.</cite></li></ul>

<div role="navigation" class="navbox" aria-labelledby="Targeted_cancer_therapy_/_antineoplastic_agents_(L01)" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Targeted_cancer_therapy_/_antineoplastic_agents_(L01)" style="font-size:114%;margin:0 4em">Targeted cancer therapy / antineoplastic agents (L01)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">CI monoclonal antibodies ("-mab")</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Receptor tyrosine kinase</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>ErbB: <i>HER1/EGFR</i> (<a href="Cetuximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Cetuximab" title="Cetuximab">Cetuximab</a></li>
<li>Panitumumab)</li>
<li><i>HER2/neu</i> (Pertuzumab, <a href="Trastuzumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Trastuzumab" title="Trastuzumab">Trastuzumab</a> (+hyaluronidase)</li>
<li>Trastuzumab emtansine)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Others for solid tumors</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>EpCAM</i> (Catumaxomab</li>
<li>Edrecolomab)</li>
<li><i>VEGF-A</i> (Bevacizumab)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Leukemia/lymphoma</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>lymphoid: <i>CD20</i> (<a href="Ibritumomab_tiuxetan.htm" tppabs="https://ptable.com/wiki/compounds/A/Ibritumomab_tiuxetan" title="Ibritumomab tiuxetan">Ibritumomab</a></li>
<li>Obinutuzumab</li>
<li>Ofatumumab</li>
<li><a href="Rituximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Rituximab" title="Rituximab">Rituximab</a></li>
<li><a href="Tositumomab.htm" tppabs="https://ptable.com/wiki/compounds/A/Tositumomab" title="Tositumomab">Tositumomab</a>), <i>CD30</i> (Brentuximab), <i>CD52</i> (<a href="Alemtuzumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Alemtuzumab" title="Alemtuzumab">Alemtuzumab</a>)</li></ul>

<ul><li>myeloid: <i>CD33</i> (Gemtuzumab)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Tyrosine kinase inhibitors ("-nib")</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Receptor tyrosine kinase</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>ErbB: <i>HER1/EGFR</i> (Brigatinib</li>
<li>Dacomitinib</li>
<li><a href="Erlotinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Erlotinib" title="Erlotinib">Erlotinib</a></li>
<li><a href="Gefitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Gefitinib" title="Gefitinib">Gefitinib</a></li>
<li>Olmutinib</li>
<li>Osimertinib</li>
<li>Rociletinib</li>
<li>Vandetanib)</li>
<li><i>HER1/EGFR and HER2/neu</i>
<ul><li>Afatinib</li>
<li><a href="Lapatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Lapatinib" title="Lapatinib">Lapatinib</a></li>
<li>Neratinib</li></ul></li></ul>

<ul><li>RTK class III: <i>C-kit and PDGFR</i> (Axitinib</li>
<li>Masitinib</li>
<li>Pazopanib</li>
<li>Ripretinib</li>
<li><a href="Sorafenib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li><a href="Sunitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sunitinib" title="Sunitinib">Sunitinib</a></li>
<li>Toceranib)</li>
<li><i>FLT3</i> (Lestaurtinib)</li></ul>

<ul><li><i>VEGFR</i>
<ul><li>Axitinib</li>
<li>Cediranib</li>
<li>Lenvatinib</li>
<li>Nintedanib</li>
<li>Pazopanib</li>
<li>Regorafenib</li>
<li>Semaxanib</li>
<li><a href="Sorafenib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li><a href="Sunitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sunitinib" title="Sunitinib">Sunitinib</a></li>
<li>Tivozanib</li>
<li>Toceranib</li>
<li>Vandetanib</li></ul></li></ul>

<ul><li><i>ALK</i> 
<ul><li>Alectinib</li>
<li>Brigatinib</li>
<li>Ceritinib</li></ul></li></ul>

<p><i>RET inhibitors:</i> Entrectinib (ALK, ROS1, NTRK), Pemigatinib (FGFR), Selpercatinib (VEGFR, FGFR), Vandetanib (VEGFR, EGFR).
<i>c-MET inhibitors:</i> Cabozantinib (VEGFR), Capmatinib, Crizotinib (ALK)</p>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Non-receptor</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>bcr-abl</i>
<ul><li>Bosutinib</li>
<li><a href="Dasatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Dasatinib" title="Dasatinib">Dasatinib</a></li>
<li><a href="Imatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Imatinib" title="Imatinib">Imatinib</a></li>
<li>Nilotinib</li>
<li>Ponatinib</li>
<li>Radotinib</li></ul></li></ul>

<ul><li><i>Src</i> (Bosutinib</li>
<li><a href="Dasatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Dasatinib" title="Dasatinib">Dasatinib</a>)</li></ul>

<ul><li><i>Janus kinase</i>
<ul><li>Lestaurtinib</li>
<li>Momelotinib</li>
<li>Pacritinib</li>
<li>Ruxolitinib</li></ul></li></ul>

<ul><li><i>MAP2K</i>
<ul><li>Binimetinib</li>
<li>Cobimetinib</li>
<li>Selumetinib</li>
<li>Trametinib</li></ul></li></ul>

<ul><li><i>EML4-ALK</i>
<ul><li>Crizotinib</li>
<li>Entrectinib</li>
<li>Lorlatinib</li></ul></li></ul>

<ul><li><i>Bruton's</i>
<ul><li>Acalabrutinib</li>
<li>Ibrutinib</li></ul></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>fusion protein against VEGF</i> (Aflibercept)</li>
<li><i>proapoptotic peptide against ANXA2 and prohibitin</i> (Adipotide)</li>
<li><i>exotoxin against <a href="Interleukin_2.htm" tppabs="https://ptable.com/wiki/compounds/A/Interleukin_2" title="Interleukin 2">IL-2</a></i> (<a href="Denileukin_diftitox.htm" tppabs="https://ptable.com/wiki/compounds/A/Denileukin_diftitox" title="Denileukin diftitox">Denileukin diftitox</a>)</li>
<li><i>mTOR inhibitors</i>
<ul><li><a href="Everolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Everolimus" title="Everolimus">Everolimus</a></li>
<li><a href="Temsirolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Temsirolimus" title="Temsirolimus">Temsirolimus</a></li></ul></li>
<li><i>hedgehog inhibitors</i>
<ul><li>Sonidegib</li>
<li>Vismodegib</li></ul></li>
<li><i>CDK inhibitor</i> (Palbociclib</li>
<li>Ribociclib)</li>
<li>Venetoclax</li></ul>
</div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Growth_factor_receptor_modulators" style="padding:3px"><table class="nowraplinks hlist mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Growth_factor_receptor_modulators" style="font-size:114%;margin:0 4em">Growth factor receptor modulators</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Angiopoietin</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Angiopoietin 1</li>
<li>Angiopoietin 4</li></ul>

<ul><li><i>Antagonists:</i> Angiopoietin 2</li>
<li><span class="new">Angiopoietin 3</span></li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Altiratinib</span></li>
<li><span class="new">CE-245677</span></li>
<li>Rebastinib</li></ul>

<ul><li><i>Antibodies:</i> Evinacumab (against angiopoietin 3)</li>
<li>Nesvacumab (against angiopoietin 2)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">CNTF</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Axokine</li>
<li>CNTF</li>
<li><span class="new">Dapiclermin</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">EGF (ErbB)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">EGF<br><small>(ErbB1/HER1)</small></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists</i>: Amphiregulin</li>
<li>Betacellulin</li>
<li>EGF (urogastrone)</li>
<li>Epigen</li>
<li>Epiregulin</li>
<li>Heparin-binding EGF-like growth factor (HB-EGF)</li>
<li>Murodermin</li>
<li>Nepidermin</li>
<li>Transforming growth factor alpha (TGFα)</li></ul>

<ul><li><i>Kinase inhibitors:</i> Afatinib</li>
<li><span class="new">AG-490</span></li>
<li><span class="new">Agerafenib</span></li>
<li>Brigatinib</li>
<li>Canertinib</li>
<li>Dacomitinib</li>
<li><a href="Erlotinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Erlotinib" title="Erlotinib">Erlotinib</a></li>
<li><a href="Gefitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Gefitinib" title="Gefitinib">Gefitinib</a></li>
<li>Grandinin</li>
<li>Icotinib</li>
<li><a href="Lapatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Lapatinib" title="Lapatinib">Lapatinib</a></li>
<li>Neratinib</li>
<li>Osimertinib</li>
<li>Vandetanib</li>
<li><span class="new">WHI-P 154</span></li></ul>

<ul><li><i>Antibodies:</i> <a href="Cetuximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Cetuximab" title="Cetuximab">Cetuximab</a></li>
<li><span class="new">Depatuxizumab</span></li>
<li>Depatuxizumab mafodotin</li>
<li>Futuximab</li>
<li>Imgatuzumab</li>
<li>Matuzumab</li>
<li>Necitumumab</li>
<li>Nimotuzumab</li>
<li>Panitumumab</li>
<li>Zalutumumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">ErbB2/HER2</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists</i>: <i>Unknown/none</i></li></ul>

<ul><li><i>Antibodies:</i> Ertumaxomab</li>
<li>Pertuzumab</li>
<li><a href="Trastuzumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Trastuzumab" title="Trastuzumab">Trastuzumab</a></li>
<li><span class="new">Trastuzumab duocarmazine</span></li>
<li>Trastuzumab emtansine</li></ul>

<ul><li><i>Kinase inhibitors:</i> Afatinib</li>
<li><span class="new">AG-490</span></li>
<li><a href="Lapatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Lapatinib" title="Lapatinib">Lapatinib</a></li>
<li>Mubritinib</li>
<li>Neratinib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">ErbB3/HER3</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Neuregulins (heregulins) (1, 2, 6 (neuroglycan C))</li></ul>

<ul><li><i>Antibodies:</i> Duligotumab</li>
<li>Patritumab</li>
<li>Seribantumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">ErbB4/HER4</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Betacellulin</li>
<li>Epigen</li>
<li>Heparin-binding EGF-like growth factor (HB-EGF)</li>
<li>Neuregulins (heregulins) (1, 2, 3, 4, <span class="new">5 (tomoregulin, TMEFF)</span>)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">FGF</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">FGFR1</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Ersofermin</span></li>
<li>FGF (1, 2 (bFGF), 3, 4, 5, 6, 8, 10 (KGF2), 20)</li>
<li><span class="new">Repifermin</span></li>
<li>Selpercatinib</li>
<li>Trafermin</li>
<li><span class="new">Velafermin</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">FGFR2</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Ersofermin</span></li>
<li>FGF (1, 2 (bFGF), 3, 4, 5, 6, 7 (KGF), 8, 9, 10 (KGF2), 17, 18, 22)</li>
<li><a href="Palifermin.htm" tppabs="https://ptable.com/wiki/compounds/A/Palifermin" title="Palifermin">Palifermin</a></li>
<li><span class="new">Repifermin</span></li>
<li>Selpercatinib</li>
<li>Sprifermin</li>
<li>Trafermin</li></ul>

<ul><li><i>Antibodies:</i> <span class="new">Aprutumab</span></li>
<li><span class="new">Aprutumab ixadotin</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">FGFR3</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Ersofermin</span></li>
<li>FGF (1, 2 (bFGF), 4, 8, 9, 18, 23)</li>
<li>Selpercatinib</li>
<li>Sprifermin</li>
<li>Trafermin</li></ul>

<ul><li><i>Antibodies:</i> Burosumab (against FGF23)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">FGFR4</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Ersofermin</span></li>
<li>FGF (1, 2 (bFGF), 4, 6, 8, 9, 19)</li>
<li>Trafermin</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Unsorted</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> FGF15/19</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">HGF (c-Met)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists</i>: Hepatocyte growth factor</li></ul>

<ul><li><i>Potentiators:</i> Dihexa (PNB-0408)</li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Altiratinib</span></li>
<li><span class="new">AM7</span></li>
<li><span class="new">AMG-458</span></li>
<li><span class="new">Amuvatinib</span></li>
<li><span class="new">BMS-777607</span></li>
<li>Cabozantinib</li>
<li>Crizotinib</li>
<li>Foretinib</li>
<li><span class="new">Golvatinib</span></li>
<li><span class="new">INCB28060</span></li>
<li><span class="new">JNJ-38877605</span></li>
<li><a href="K252a.htm" tppabs="https://ptable.com/wiki/compounds/A/K252a" title="K252a">K252a</a></li>
<li><span class="new">MK-2461</span></li>
<li><span class="new">PF-04217903</span></li>
<li><span class="new">PF-2341066</span></li>
<li><span class="new">PHA-665752</span></li>
<li><span class="new">SU-11274</span></li>
<li>Tivantinib</li>
<li>Volitinib</li></ul>

<ul><li><i>Antibodies:</i> Emibetuzumab</li>
<li>Ficlatuzumab</li>
<li>Flanvotumab</li>
<li>Onartuzumab</li>
<li>Rilotumumab</li>
<li><span class="new">Telisotuzumab</span></li>
<li><span class="new">Telisotuzumab vedotin</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IGF</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IGF-1</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists</i>: des(1-3)IGF-1</li>
<li>Insulin-like growth factor-1 (somatomedin C)</li>
<li>IGF-1 LR3</li>
<li>Insulin-like growth factor-2 (somatomedin A)</li>
<li><a href="Insulin.htm" tppabs="https://ptable.com/wiki/compounds/A/Insulin" title="Insulin">Insulin</a></li>
<li><a href="Mecasermin.htm" tppabs="https://ptable.com/wiki/compounds/A/Mecasermin" title="Mecasermin">Mecasermin</a></li>
<li>Mecasermin rinfabate</li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">BMS-754807</span></li>
<li>Linsitinib</li>
<li><span class="new">NVP-ADW742</span></li>
<li><span class="new">NVP-AEW541</span></li>
<li><span class="new">OSl-906</span></li></ul>

<ul><li><i>Antibodies:</i> <span class="new">AVE-1642</span></li>
<li>Cixutumumab</li>
<li>Dalotuzumab</li>
<li>Figitumumab</li>
<li>Ganitumab</li>
<li>Robatumumab</li>
<li><span class="new">R1507</span></li>
<li>Teprotumumab</li>
<li><span class="new">Xentuzumab</span> (against IGF-1 and IGF-2)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IGF-2</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists</i>: Insulin-like growth factor-2 (somatomedin A)</li></ul>

<ul><li><i>Antibodies:</i> Dusigitumab</li>
<li><span class="new">Xentuzumab</span> (against IGF-1 and IGF-2)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Others</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Binding proteins:</i> IGFBP (1, 2, 3, 4, 5, 6, 7)</li></ul>

<ul><li><i>Cleavage products/derivatives with unknown target:</i> <span class="new">Glypromate (GPE, (1-3)IGF-1)</span></li>
<li>Trofinetide</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">LNGF (p75<sup>NTR</sup>)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> BDNF</li>
<li>BNN-20</li>
<li>BNN-27</li>
<li>Cenegermin</li>
<li><a href="Dehydroepiandrosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone" title="Dehydroepiandrosterone">DHEA</a></li>
<li><a href="Dehydroepiandrosterone_sulfate.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone_sulfate" title="Dehydroepiandrosterone sulfate">DHEA-S</a></li>
<li>NGF</li>
<li>NT-3</li>
<li>NT-4</li></ul>

<ul><li><i>Antagonists:</i> <span class="new">ALE-0540</span></li>
<li><a href="Dexamethasone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dexamethasone" title="Dexamethasone">Dexamethasone</a></li>
<li><span class="new">EVT-901 (SAR-127963)</span></li>
<li><a href="Testosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Testosterone" title="Testosterone">Testosterone</a></li></ul>

<ul><li><i>Antibodies:</i> <i>Against NGF:</i> <span class="new">ABT-110 (PG110)</span></li>
<li><span class="new">ASP-6294</span></li>
<li>Fasinumab</li>
<li><span class="new">Frunevetmab</span></li>
<li>Fulranumab</li>
<li><span class="new">MEDI-578</span></li>
<li><span class="new">Ranevetmab</span></li>
<li>Tanezumab</li></ul>

<ul><li><i>Aptamers:</i> <i>Against NGF:</i> <span class="new">RBM-004</span></li></ul>

<ul><li><i>Decoy receptors:</i> <span class="new">LEVI-04 (p75<sup>NTR</sup>-Fc)</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">PDGF</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <a href="Becaplermin.htm" tppabs="https://ptable.com/wiki/compounds/A/Becaplermin" title="Becaplermin">Becaplermin</a></li>
<li>Platelet-derived growth factor (A, B, C, D)</li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Agerafenib</span></li>
<li>Axitinib</li>
<li>Crenolanib</li>
<li><a href="Imatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Imatinib" title="Imatinib">Imatinib</a></li>
<li>Lenvatinib</li>
<li>Masitinib</li>
<li>Motesanib</li>
<li>Nintedanib</li>
<li>Pazopanib</li>
<li>Radotinib</li>
<li>Quizartinib</li>
<li>Ripretinib</li>
<li><a href="Sunitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sunitinib" title="Sunitinib">Sunitinib</a></li>
<li><a href="Sorafenib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li>Toceranib</li></ul>

<ul><li><i>Antibodies:</i> Olaratumab</li>
<li>Ramucirumab</li>
<li>Tovetumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">RET (GFL)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">GFRα1</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Glial cell line-derived neurotrophic factor (GDNF)</li>
<li><span class="new">Liatermin</span></li></ul>

<ul><li><i>Kinase inhibitors:</i> Vandetanib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">GFRα2</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Neurturin (NRTN)</li></ul>

<ul><li><i>Kinase inhibitors:</i> Vandetanib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">GFRα3</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Artemin (ARTN)</li></ul>

<ul><li><i>Kinase inhibitors:</i> Vandetanib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">GFRα4</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Persephin (PSPN)</li></ul>

<ul><li><i>Kinase inhibitors:</i> Vandetanib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Unsorted</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Kinase inhibitors:</i> <span class="new">Agerafenib</span></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">SCF (c-Kit)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Ancestim</li>
<li>Stem cell factor</li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Agerafenib</span></li>
<li>Axitinib</li>
<li><a href="Dasatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Dasatinib" title="Dasatinib">Dasatinib</a></li>
<li><a href="Imatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Imatinib" title="Imatinib">Imatinib</a></li>
<li>Masitinib</li>
<li>Nilotinib</li>
<li>Pazopanib</li>
<li>Quizartinib</li>
<li><a href="Sorafenib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li><a href="Sunitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sunitinib" title="Sunitinib">Sunitinib</a></li>
<li>Toceranib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">TGFβ</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Trk</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">TrkA</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <a href="Amitriptyline.htm" tppabs="https://ptable.com/wiki/compounds/A/Amitriptyline" title="Amitriptyline">Amitriptyline</a></li>
<li>BNN-20</li>
<li>BNN-27</li>
<li>Cenegermin</li>
<li><a href="Dehydroepiandrosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone" title="Dehydroepiandrosterone">DHEA</a></li>
<li><a href="Dehydroepiandrosterone_sulfate.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone_sulfate" title="Dehydroepiandrosterone sulfate">DHEA-S</a></li>
<li><span class="new">Gambogic amide</span></li>
<li>NGF</li>
<li>Tavilermide</li></ul>

<ul><li><i>Antagonists:</i> <span class="new">ALE-0540</span></li>
<li><a href="Dexamethasone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dexamethasone" title="Dexamethasone">Dexamethasone</a></li>
<li>FX007</li>
<li><a href="Testosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Testosterone" title="Testosterone">Testosterone</a></li></ul>

<ul><li><i>Negative allosteric modulators:</i> <span class="new">VM-902A</span></li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Altiratinib</span></li>
<li><span class="new">AZD-6918</span></li>
<li><span class="new">CE-245677</span></li>
<li><span class="new">CH-7057288</span></li>
<li><span class="new">DS-6051</span></li>
<li>Entrectinib</li>
<li><span class="new">GZ-389988</span></li>
<li><a href="K252a.htm" tppabs="https://ptable.com/wiki/compounds/A/K252a" title="K252a">K252a</a></li>
<li>Larotrectinib</li>
<li>Lestaurtinib</li>
<li><span class="new">Milciclib</span></li>
<li><span class="new">ONO-4474</span></li>
<li><span class="new">ONO-5390556</span></li>
<li><span class="new">PLX-7486</span></li>
<li>Rebastinib</li>
<li><span class="new">SNA-120 (pegylated K252a)</span>)</li></ul>

<ul><li><i>Antibodies:</i> <i>Against TrkA:</i> <span class="new">GBR-900</span>; <i>Against NGF:</i> <span class="new">ABT-110 (PG110)</span></li>
<li><span class="new">ASP-6294</span></li>
<li>Fasinumab</li>
<li><span class="new">Frunevetmab</span></li>
<li>Fulranumab</li>
<li><span class="new">MEDI-578</span></li>
<li><span class="new">Ranevetmab</span></li>
<li>Tanezumab</li></ul>

<ul><li><i>Aptamers:</i> <i>Against NGF:</i> <span class="new">RBM-004</span></li></ul>

<ul><li><i>Decoy receptors:</i> <span class="new">ReN-1820 (TrkAd5)</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">TrkB</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">3,7-DHF</span></li>
<li><span class="new">3,7,8,2'-THF</span></li>
<li>4'-DMA-7,8-DHF</li>
<li><span class="new">7,3'-DHF</span></li>
<li>7,8-DHF</li>
<li><span class="new">7,8,2'-THF</span></li>
<li>7,8,3'-THF</li>
<li><a href="Amitriptyline.htm" tppabs="https://ptable.com/wiki/compounds/A/Amitriptyline" title="Amitriptyline">Amitriptyline</a></li>
<li>BDNF</li>
<li>BNN-20</li>
<li>Deoxygedunin</li>
<li><a href="Selegiline.htm" tppabs="https://ptable.com/wiki/compounds/A/Deprenyl" title="Deprenyl" class="mw-redirect">Deprenyl</a></li>
<li>Diosmetin</li>
<li><span class="new">DMAQ-B1</span></li>
<li>HIOC</li>
<li>LM22A-4</li>
<li><a href="N-Acetylserotonin.htm" tppabs="https://ptable.com/wiki/compounds/A/N-Acetylserotonin" title="N-Acetylserotonin">N-Acetylserotonin</a></li>
<li>NT-3</li>
<li>NT-4</li>
<li>Norwogonin (5,7,8-THF)</li>
<li>R7</li>
<li>R13</li>
<li><span class="new">TDP6</span></li></ul>

<ul><li><i>Antagonists:</i> ANA-12</li>
<li>Cyclotraxin B</li>
<li>Gossypetin (3,5,7,8,3',4'-HHF)</li></ul>

<ul><li><i>Ligands:</i> <a href="Dehydroepiandrosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone" title="Dehydroepiandrosterone">DHEA</a></li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Altiratinib</span></li>
<li><span class="new">AZD-6918</span></li>
<li><span class="new">CE-245677</span></li>
<li><span class="new">CH-7057288</span></li>
<li><span class="new">DS-6051</span></li>
<li>Entrectinib</li>
<li><span class="new">GZ-389988</span></li>
<li><a href="K252a.htm" tppabs="https://ptable.com/wiki/compounds/A/K252a" title="K252a">K252a</a></li>
<li>Larotrectinib</li>
<li>Lestaurtinib</li>
<li><span class="new">ONO-4474</span></li>
<li><span class="new">ONO-5390556</span></li>
<li><span class="new">PLX-7486</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">TrkC</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> BNN-20</li>
<li><a href="Dehydroepiandrosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone" title="Dehydroepiandrosterone">DHEA</a></li>
<li>NT-3</li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Altiratinib</span></li>
<li><span class="new">AZD-6918</span></li>
<li><span class="new">CE-245677</span></li>
<li><span class="new">CH-7057288</span></li>
<li><span class="new">DS-6051</span></li>
<li>Entrectinib</li>
<li><span class="new">GZ-389988</span></li>
<li><a href="K252a.htm" tppabs="https://ptable.com/wiki/compounds/A/K252a" title="K252a">K252a</a></li>
<li>Larotrectinib</li>
<li>Lestaurtinib</li>
<li><span class="new">ONO-4474</span></li>
<li><span class="new">ONO-5390556</span></li>
<li><span class="new">PLX-7486</span></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">VEGF</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Placental growth factor (PGF)</li>
<li>Ripretinib</li>
<li><span class="new">Telbermin</span></li>
<li>VEGF (A, B, C, D (FIGF))</li></ul>

<ul><li><i>Allosteric modulators:</i> Cyclotraxin B</li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Agerafenib</span></li>
<li><span class="new">Altiratinib</span></li>
<li>Axitinib</li>
<li>Cabozantinib</li>
<li>Cediranib</li>
<li><a href="Lapatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Lapatinib" title="Lapatinib">Lapatinib</a></li>
<li>Lenvatinib</li>
<li>Motesanib</li>
<li>Nintedanib</li>
<li>Pazopanib</li>
<li>Pegaptanib</li>
<li>Rebastinib</li>
<li>Regorafenib</li>
<li>Semaxanib</li>
<li><a href="Sorafenib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li><a href="Sunitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sunitinib" title="Sunitinib">Sunitinib</a></li>
<li>Toceranib</li>
<li>Tivozanib</li>
<li>Vandetanib</li>
<li><span class="new">WHI-P 154</span></li></ul>

<ul><li><i>Antibodies:</i> Alacizumab pegol</li>
<li>Bevacizumab</li>
<li>Icrucumab</li>
<li>Ramucirumab</li>
<li><a href="Ranibizumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Ranibizumab" title="Ranibizumab">Ranibizumab</a></li></ul>

<ul><li><i>Decoy receptors:</i> Aflibercept</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Others</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Additional growth factors:</i> Adrenomedullin</li>
<li>Colony-stimulating factors (see here instead)</li>
<li>Connective tissue growth factor (CTGF)</li>
<li>Ephrins (A1, A2, A3, A4, A5, B1, B2, B3)</li>
<li>Erythropoietin (see here instead)</li>
<li>Glucose-6-phosphate isomerase (GPI; PGI, PHI, AMF)</li>
<li>Glia maturation factor (GMF)</li>
<li>Hepatoma-derived growth factor (HDGF)</li>
<li>Interleukins/T-cell growth factors (see here instead)</li>
<li>Leukemia inhibitory factor (LIF)</li>
<li>Macrophage-stimulating protein (MSP; HLP, HGFLP)</li>
<li>Midkine (NEGF2)</li>
<li>Migration-stimulating factor (MSF; PRG4)</li>
<li>Oncomodulin</li>
<li>Pituitary adenylate cyclase-activating peptide (PACAP)</li>
<li>Pleiotrophin</li>
<li>Renalase</li>
<li>Thrombopoietin (see here instead)</li>
<li>Wnt signaling proteins</li></ul>

<ul><li><i>Additional growth factor receptor modulators:</i> Cerebrolysin (neurotrophin mixture)</li></ul>
</div></td></tr><tr><td class="navbox-abovebelow" colspan="2"><div>
<dl><dt>See also</dt>
<dd><i>Receptor/signaling modulators</i></dd>
<dd><i>Signaling peptide/protein receptor modulators</i></dd>
<dd><i>Cytokine receptor modulators</i></dd></dl>
</div></td></tr></tbody></table></div>












<style data-mw-deduplicate="TemplateStyles:r951705291">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg*/);background-repeat:no-repeat;background-size:12px;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style>
    
</details></div>
        </div>
      </div>
    </div>
  </div>
  <script src="../-/j/js_modules/jsConfigVars.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jsConfigVars.js" class=""></script>
  <script src="../-/j/js_modules/startup.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/startup.js" class=""></script>
<script src="../-/j/js_modules/jquery.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jquery.js" class=""></script>
<script src="../-/j/js_modules/mediawiki.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/mediawiki.js" class=""></script>
<script src="../-/j/js_modules/site.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/site.js" class=""></script>
<script src="../-/j/js_modules/ext.cite.ux-enhancements.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/ext.cite.ux-enhancements.js" class=""></script>



</body></html>